The oncology landscape for breast cancer is rapidly evolving. Today, the primary challenge is not only developing new medications, but also determining their optimal sequence and combination. The studies scheduled for presentation at the European Society for Medical Oncology (ESMO) 2026 Congress address these exact questions: when traditional chemotherapy can be reduced or replaced with targeted agents, how to manage the disease after it develops resistance to certain drugs, and how to select the next step of treatment based on individual patient and disease characteristics.
The studies presented here may shape modern treatment standards and practical perspectives in breast cancer care.
TALENT: Chemotherapy Optimization and Replacement Prospects in Early Stages
Traditional chemotherapy damages healthy tissues alongside cancer cells, causing various side effects. A key direction in modern oncology is the use of agents that target specific molecules on cancer cells.
Among these are antibody-drug conjugates (ADCs)—medications combining a targeting antibody with a cytotoxic agent. The TALENT trial evaluates the use of T-DXd in hormone receptor–positive (HR-positive) and HER2-low breast cancer.
The study is conducted in the neoadjuvant setting (treatment given prior to primary surgery). It evaluates various T-DXd strategies, including its combination with endocrine therapy.
The aim is to determine whether standard chemotherapy can be reduced or entirely avoided in certain patient populations using T-DXd–based regimens.
NATALEE: Long-Term Efficacy of Ribociclib in Early Breast Cancer
A key challenge in managing early-stage breast cancer is preventing disease recurrence after surgery. In HR-positive, HER2-negative breast cancer, standard endocrine therapy reduces recurrence risk, yet evaluating the long-term benefit and efficacy of additional agents remains crucial.
The study evaluated the combination of the CDK4/6 inhibitor ribociclib and standard endocrine therapy in patients with HR-positive, HER2-negative early breast cancer. Ribociclib blocks CDK4/6 enzyme activity, inhibiting cancer cell proliferation. The 6-year follow-up data are particularly important for assessing whether treatment benefits are sustained long-term and whether adding ribociclib improves overall survival (OS).
PANKU-Breast01: Efficacy of Izalontamab Brengitecan in Previously Treated HR-Positive, HER2-Negative Breast Cancer
In metastatic HR-positive, HER2-negative breast cancer, a major challenge is controlling disease progression, especially after multiple prior regimens where resistance or progression has developed.
PANKU-Breast01 (LBA50) is a randomized Phase III trial evaluating the efficacy and safety of izalontamab brengitecan (an antibody-drug conjugate) in heavily pretreated, unresectable, locally advanced, or metastatic HR-positive, HER2-negative breast cancer. The trial aims to establish the drug’s effectiveness in patients who have received various endocrine and targeted therapy combinations and require viable subsequent options.
KEYNOTE-B49 (LBA51): Pembrolizumab in HR-Positive, HER2-Negative Advanced Breast Cancer
Immunotherapy is established in triple-negative breast cancer—a subtype lacking estrogen receptors, progesterone receptors, and HER2 protein, rendering endocrine and HER2-targeted therapies ineffective. However, whether adding immunotherapy provides clinical benefit in HR-positive, HER2-negative breast cancer remains under evaluation.
KEYNOTE-B49 (LBA51) is a randomized, double-blind Phase III trial evaluating the efficacy of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with HR-positive, HER2-negative advanced breast cancer.
If positive, the magnitude of benefit and identification of predictive biomarkers will be critical. If negative, the findings will highlight the challenge of applying immunotherapy to this subtype and the need for more precise biological selection.
FINER (LBA14): Overall Survival Outcomes with Fulvestrant plus Ipatasertib
FINER (CCTG/BCT MA.40) is a randomized Phase III trial evaluating overall survival (OS) with fulvestrant plus ipatasertib in HER2-negative, ER-positive metastatic breast cancer.
Combining these two agents creates a dual attack: endocrine therapy (fulvestrant) blocks estrogen receptors, while the targeted agent (ipatasertib) inhibits the bypass Akt signaling pathway. This combination helps overcome endocrine resistance.
In metastatic HR-positive disease, where patients receive multiple sequential lines of therapy, improving overall survival is far more difficult than delaying disease progression. Therefore, the final OS analysis presented at ESMO 2026 is of high scientific interest.
The FINER results will help clinicians better evaluate the long-term clinical benefit of this endocrine and targeted therapy combination and define its exact role in current metastatic breast cancer treatment algorithms.
VIKTORIA-1 (LBA16): Updated Phase III Results Following Endocrine Resistance
VIKTORIA-1 (LBA16) is a randomized Phase III trial comparing the combination of gedatolisib and fulvestrant, with or without palbociclib, against standard treatment in patients with HR-positive, HER2-negative advanced breast cancer.
This trial addresses one of modern oncology’s most difficult questions: how to treat patients whose disease has progressed on endocrine therapy and CDK4/6 inhibitors. CDK4/6 inhibitors (such as palbociclib) target enzymes responsible for cell division to arrest tumor proliferation.
The trial design evaluates gedatolisib plus fulvestrant both with and without a CDK4/6 inhibitor. The updated analysis will help answer key clinical questions, such as whether cell-cycle inhibition should be maintained after progression or whether treatment should shift to alternative pathway blockade.
evERA Breast Cancer (2RO): From Efficacy to Biomarker Selection
This presentation covers a Phase III retrospective exploratory biomarker analysis evaluating giredestrant (an oral selective estrogen receptor degrader) combined with everolimus (an oral targeted agent blocking bypass signaling pathways for tumor growth and survival) in ER-positive, HER2-negative advanced breast cancer following CDK4/6 inhibitor therapy.
Unlike other studies in this lineup, the primary focus of these ESMO data is identifying biological markers that predict treatment response rather than simply reassessing overall efficacy.
This makes evERA particularly relevant for post-CDK4/6 inhibitor strategy development. As endocrine and targeted options expand, treatment selection will increasingly rely on identifying specific resistance mechanisms rather than applying a single standard regimen to all patients.
While exploratory, these biomarkers could lay the groundwork for more personalized treatment selection.
postMONARCH (1RO): Overall Survival Following Prior CDK4/6 Inhibitors
This presentation delivers overall survival (OS) results from a Phase III trial comparing abemaciclib (a CDK4/6 inhibitor) plus fulvestrant against placebo plus fulvestrant in patients whose disease progressed on prior CDK4/6 inhibitors and endocrine therapy.
The core clinical question is practical: after disease progression on a CDK4/6 inhibitor, how effective is re-inhibiting the same pathway? Specifically, does adding abemaciclib to a new endocrine agent yield a true overall survival advantage?
This question is increasingly pressing as post-CDK4/6 treatment options diverge. Clinicians must choose among additional endocrine therapy, targeted agents, ADCs, or chemotherapy based on tumor biology and prior treatment history.
The OS analysis should help clarify whether continuing CDK4/6 inhibition provides meaningful clinical benefit beyond delaying progression.
OptiTROP-Breast01 (4639RO): Final Overall Survival in Triple-Negative Breast Cancer (TNBC)
OptiTROP-Breast01 presents the final overall survival (OS) analysis comparing sacituzumab tirumotecan (a TROP-2–directed antibody-drug conjugate) with standard chemotherapy in patients with locally recurrent or metastatic TNBC who received prior systemic chemotherapy.
This mature OS analysis is significant in modern TNBC management, where ADCs play an increasingly central role. As drugs with similar mechanisms and targets enter the market, mature survival data will be crucial for establishing proper treatment sequencing rather than simply demonstrating drug activity.
OptiTROP-Breast01 contributes key evidence regarding both drug efficacy and the broader clinical placement of ADCs in metastatic treatment sequencing.
SWITCH (LBA15): ADC Sequencing Perspectives After Prior ADC Therapy
SWITCH is conceptually one of the most important trials in the program because it directly addresses what happens after an initial ADC fails. This prospective, open-label Phase II trial evaluates target switching using novel ADCs with a preserved payload in patients with metastatic breast cancer who previously received ADC therapy (Liu et al., 2026).
This topic is urgent because ADCs are moving into earlier lines of metastatic treatment. Sequencing ADCs requires looking beyond surface target expression alone. Resistance can stem from target antigen loss, altered intracellular trafficking, linker characteristics, payload resistance, drug efflux, or a combination of these factors.
The SWITCH strategy specifically evaluates changing the target while keeping the payload class constant. Consequently, the study’s impact extends beyond individual ADCs, offering insights into whether switching the target alone is sufficient after progression on an ADC or whether changing the cytotoxic payload mechanism will also be necessary in future sequencing strategies.
The presentations selected for ESMO 2026 highlight shifting priorities in breast cancer oncology—a move toward long-term, robust overall survival outcomes and rational treatment sequencing.
In early-stage disease, TALENT evaluates integrating an ADC into the neoadjuvant setting for HER2-low patients, while NATALEE assesses adjuvant CDK4/6 inhibition over 6 years of follow-up.
In advanced HR-positive, HER2-negative disease, focus shifts to post-endocrine and post-CDK4/6 inhibitor strategies. Trials like KEYNOTE-B49, FINER (with OS data), VIKTORIA-1, evERA, and postMONARCH (with OS data) explore immunotherapy, targeted regimens, and biomarker-guided approaches to provide long-awaited survival insight.
Meanwhile, the ADC landscape continues to expand rapidly: PANKU-Breast01 evaluates a novel ADC in pretreated HR-positive disease, OptiTROP-Breast01 reports final OS in TNBC, and SWITCH tackles the next frontier—treatment after prior ADC failure.
The future of breast cancer care increasingly depends not only on selecting the right drug, but also on defining the optimal sequence of therapies across every stage of disease.
